{"entity":{"id":"nct04589234","kind":"trial","name":"Saltikva for Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Gemcitabine and Gemcitabine + nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Salspera LLC, active and no longer recruiting.","summary":"Saltikva for Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT04589234 by Salspera LLC, with 60 participants enrolled, started 2020-10-20 and due to reach its primary completion in 2030-12-31. Interventions recorded: Salmonella-IL2, FOLFIRINOX Alone (Historical Controls) and Gemcitabine/Abraxane Alone (Historical Controls).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04589234","url":"https://clinicaltrials.gov/study/NCT04589234"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04589234","phase":"2","setting":"A Phase 2 Study of Saltikva (Attenuated Salmonella Typhimurium Containing the Human Gene for Interleukin-2) in Patients With Metastatic Pancreatic Cancer","sponsor":"Salspera LLC","enrolled":60,"outcomes":[]},"route":"/trials/nct04589234/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}]}}